Could a safer drug replace standard antiviral for kidney transplant patients?
NCT ID NCT07294547
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if valacyclovir works as well as valganciclovir to prevent CMV and EBV infections in kidney transplant patients. Valganciclovir can cause bone marrow suppression, a serious side effect. The study will enroll 80 kidney transplant recipients and monitor them for new infections and side effects over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital
RECRUITINGTaipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact